Genmab
Genmab A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to developing differentiated antibody therapeutics. Founded in 1999, Genmab has made significant strides in the biopharmaceutical industry, focusing primarily on oncology and immunology. With a robust pipeline of proprietary and partnered products, Genmab's core offerings include monoclonal antibodies that target various cancers, distinguished by their unique mechanisms of action. The company has achieved notable milestones, including the successful development of its flagship product, Darzalex, which has transformed treatment paradigms for multiple myeloma. Positioned as a key player in the global biotechnology landscape, Genmab continues to expand its influence through strategic collaborations and a commitment to scientific excellence, solidifying its reputation as a pioneer in the field.
DitchCarbon Score
How does Genmab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genmab's score of 14 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genmab's reported carbon emissions
In 2023, Genmab reported total emissions of approximately 555,000 kg CO2e, comprising 317,000 kg CO2e from Scope 1 and 238,000 kg CO2e from Scope 2. This marks a continuation of their emissions tracking, as they have disclosed data for both scopes in recent years. In 2022, their total emissions were about 147,721,000 kg CO2e, with Scope 1 emissions at 283,000 kg CO2e, Scope 2 at 111,000 kg CO2e, and a significant contribution from Scope 3 emissions at approximately 147,327,000 kg CO2e. The total emissions for 2021 were about 638,700 kg CO2e, with Scope 1 at 341,000 kg CO2e and Scope 2 at 298,000 kg CO2e. Despite the detailed emissions reporting, Genmab has not set specific reduction targets or initiatives as part of their climate commitments. Their emissions per employee have shown an increase over the years, with figures of 4,160 kg CO2e in 2021, 5,440 kg CO2e in 2022, and 6,740 kg CO2e in 2023. As a company headquartered in Denmark (DK), Genmab is part of a growing trend in the biopharmaceutical industry to enhance transparency regarding carbon emissions and climate impact, although they currently lack formal reduction targets or commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 341,000 | 000,000 | 000,000 |
| Scope 2 | 298,000 | 000,000 | 000,000 |
| Scope 3 | - | 000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genmab is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
